Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CCR3 | P51677 | 2/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.61 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233563 | 0.91 | CCR3 (0.67) | KCNH2CCR3SIGMAR1TMEM97PRMT6 | |
| SCHEMBL8814813 | 0.84 | GRIN2D (0.69) | KCNH2CCR3SIGMAR1PRMT6CARM1 | |
| SCHEMBL24146287 | 0.83 | KCNH2 (0.48) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL153896 | 0.83 | KCNH2 (0.88) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7253251 | 0.82 | GRIN2D (0.67) | KCNH2CCR3SIGMAR1PRMT6CARM1 | |
| SCHEMBL349032 | 0.82 | KCNH2 (0.97) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL12041264 | 0.82 | KCNH2 (0.81) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5914355 | 0.82 | CCR3 (0.62) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5914324 | 0.82 | CCR3 (0.62) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL12041313 | 0.82 | KCNH2 (0.71) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | GPR84, GPR88, FFAR1 | KCNH2 1498/4885CCR3 1280/4885SIGMAR1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.